SARS-CoV

CAS No.	Product Name	Inquiry
1071517-39-9	Setrobuvir (ANA598) Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC50s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS- CoV-2 RdRp and induces RdRp inhibition.
1087243-14-8	GRL-0496 GRL-0496 is a potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitor, with an IC50 of 30 nM in both enzyme inhibitory and antiviral assays. GRL-0496 shows SARS-CoV antiviral activity, with an EC50 of 6.9 μM.
1092540-50-5	Atazanavir-[d6] Atazanavir-[d6] is the labelled analogue of Atazanavir. Atazanavir is a novel and potent azapeptide protease inhibitor that specifically inhibits the human immunodeficiency virus type 1 (HIV-1) protease enzyme with inhibition constant Ki of 66 nmol/L and also inhibits the viral replication of HIV-1 with 50% effective concentration EC50 ranging from 2.6 to 5.3 nmol/L. Atazanavir binds to HIV-1 protease preventing the cleavage of gag and gag-pol polyproteins, which results in the formation of immature virions in HIV-1-infected cells. Atazanavir has a different C-2 symmetric chemical structure and a generally greater antiretroviral potency in various HIV strains compared to other protease inhibitors, including indinavir, nelfinavir, ritonavir, saquinavir and amprenavir.
1092540-51-6	Atazanavir-[d9] Labelled Atazanavir. Atazanavir is a novel and potent azapeptide protease inhibitor that specifically inhibits the human immunodeficiency virus type 1 (HIV-1) protease enzyme with inhibition constant Ki of 66 nmol/L and also inhibits the viral replication of HIV-1 with 50% effective concentration EC50 ranging from 2.6 to 5.3 nmol/L. Atazanavir binds to HIV-1 protease preventing the cleavage of gag and gag-pol polyproteins, which results in the formation of immature virions in HIV-1-infected cells. Atazanavir has a different C-2 symmetric chemical structure and a generally greater antiretroviral potency in various HIV strains compared to other protease inhibitors, including indinavir, nelfinavir, ritonavir, saquinavir and amprenavir.
1092942-82-9	Imatinib-[d8] Imatinib-[d8] is the labelled analogue of Imatinib, a treatment of chronic myeloid leukemia.
1093070-10-0	PLpro-IN-1
1093070-16-6	GRL0617 GRL0617 is a potent and selective inhibitor of the protease enzyme papain-like protease (PLpro) with IC50 of 0.6 μM and Ki of 0.49 μM. It has been shown to inhibit SARS-CoV viral replication in vitro.
1101867-17-7	M56-S2 iodide
1131-64-2	Debrisoquin Debrisoquin is an adrenergic neuron-blocking drug similar in effects to guanethidine. It is an antihypertensive drug with antioxidant, anti-inflammatory, and neuroprotective properties. It can regulate the activity of certain neurotransmitters, including dopamine and serotonin, which makes it a promising candidate for treating neurological disorders, such as Parkinson's disease and depression.
1132747-14-8	Atazanavir-[d5] Labelled Atazanavir. Atazanavir is a novel and potent azapeptide protease inhibitor that specifically inhibits the human immunodeficiency virus type 1 (HIV-1) protease enzyme with inhibition constant Ki of 66 nmol/L and also inhibits the viral replication of HIV-1 with 50% effective concentration EC50 ranging from 2.6 to 5.3 nmol/L. Atazanavir binds to HIV-1 protease preventing the cleavage of gag and gag-pol polyproteins, which results in the formation of immature virions in HIV-1-infected cells. Atazanavir has a different C-2 symmetric chemical structure and a generally greater antiretroviral potency in various HIV strains compared to other protease inhibitors, including indinavir, nelfinavir, ritonavir, saquinavir and amprenavir.
1134803-16-9	Imatinib-[d4] Imatinib-[d4] is an isotopically labelled analogue of Imatinib. Imatinib is an inhibitor of multiple tyrosine kinases. It is a COVID-19-related research product.
114014-15-2	Z-Phe-Tyr(tBu)-diazomethylketone Z-Phe-Tyr(tBu)-diazomethylketone is an inhibitor of cathepsin L with selectivity for cathepsin L over cathepsin S and cathepsin B.
115464-77-2	Elopiprazole
1164478-67-4	SARS-CoV-2 3CLpro-IN-7
1166-34-3	Cinanserin Cinanserin is a 5-HT2A and 5-HT2C receptor antagonist.
117704-65-1	Pradimicin A Pradimicin A is an antibiotic produced by Actinomadura hibisca. It has strong antifungal and yeast activity.
1191237-80-5	Remdesivir-O-desphosphate-acetonide-impurity Remdesivir O-desphosphate acetonide impurity is an impurity of Remdesivir. Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity and is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.
1191252-49-9	IOWH032 iOWH-032 is a novel and potent CFTR inhibitor (IC50=1.01 uM) in T84 and CHO-CFTR cell based assays.
119670-30-3	Z-LVG-CHN2 Z-LVG-CHN2 is a tripeptide derivative that mimics part of the human cysteine proteinase-binding center. Z-LVG-CHN2 effectively blocks SARS-COV-2 replication (EC50 = 190 nM) via inhibition of SARS-COV-2 3CL pro protease.
1206524-86-8	MK-5172 potassium salt In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose.

※ Please kindly note that our services are for research use only.